Regenerative focus Target pharmaceutical and biotech buyers interested in regenerative biologics and exosome-based therapies, leveraging Organicell's Zofin platform and perinatal exosome products to address chronic diseases and inflammatory conditions.

Clinical stage advantage Position sales discussions around late-stage development capabilities, clinical insights, and potential partnerships or licensing for Zofin and associated autologous products to accelerate clinical adoption and market entry.

Strategic partnerships Explore collaborations with beauty, skincare, and wellness players (as evidenced by Hydrafacial and Beauty Health partnerships) to co-develop exosome boosters and regenerative therapies for skin aging and inflammation markets.

SMB to mid-market Given a lean team and mid-range revenue, pursue API and technology licensing, contract research, or clinical services agreements that align with the company’s niche capabilities and scalable models.

Expansion signals Capitalize on recent leadership hires in science and executive leadership as a buying signal for potential joint ventures, strategic investments, or advisory partnerships to de-risk collaboration and co-innovation efforts.